Advertisement


John V. Cox, DO, MBA, on 2017 Quality Care Symposium Highlights: Expert Perspective

2017 Quality Care Symposium

Advertisement

John V. Cox, DO, MBA, of the Parkland Health System/UTSW, discusses some of the key presentations at the 2017 Quality Care Symposium (Abstracts 3, 37, 52).



Related Videos

Breast Cancer
Prostate Cancer
Issues in Oncology

Diana D. Jeffery, PhD, on Mental Health Comorbidities: Predictors of Cost and Utilization

Diana D. Jeffery, PhD, of the Defense Health Agency, discusses the need to screen for mental health comorbidities, including depression, anxiety, adjustment disorders, substance use disorders, and persistent mental illnesses, as shown in a study of breast and prostate cancer patients (Abstract 18).

Issues in Oncology

Greg D. Judy, MD, on Safety Incidents in Radiotherapy

Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.

Symptom Management

Ethan M. Basch, MD, on Symptom Control and Quality: The Patient’s Voice

Ethan M. Basch, MD, of The University of North Carolina at Chapel Hill, discusses programs—now rolling out at various institutions—that use direct patient reporting of symptoms as a part of quality assessment (Posters 61, 81; Abstract 218).

Issues in Oncology

Blase N. Polite, MD, MPP: The Oncology Care Model in Academia

Blase N. Polite, MD, MPP, of the University of Chicago, discusses implementing the Oncology Care Model in an academic health center and the challenges of getting buy-in from faculty members.

Issues in Oncology
Lung Cancer

Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).

Advertisement

Advertisement




Advertisement